This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
TEVA announced on July 27th its intention to withdraw its unsolicited expression of interest to acquire rival Mylan N.V., a leading global pharmaceutical company with a growing portfolio of around 1,400 generic pharmaceuticals and brand medications.
A CRA team provided economic support to Mylan in its antitrust defense in front of the European Commission against the attempted hostile take-over.
Pass-through determines how consumers respond to taxes. In a recent working paper, we investigate the impact of imperfect price information on pass-through of...
To assist policy makers in creating a policy environment that facilitates and encourages investment and innovation in Germany, Charles River Associates...
The Annual CRA Brussels Conference returns to the Steigenberger Wiltcher’s Hotel on Wednesday 6 December 2023. This year’s conference will address the state...
CRA is a proud sponsor of the event. Chara Tzanetaki is a panelist during the session titled “Mergers – technology and innovation affecting market...
